Aqueous solubility dictates downstream formulation choices for sulfachloropyridazine sodium. Water-soluble oral powder for poultry drinking water is produced by dry blending the API with buffering and anti-caking excipients. The applicable compliance baseline includes ICH Q7 for API-derived operations and Ph. Eur. 2.9.31 for bulk and tapped density; sachet filling is controlled under Ph. Eur. 2.9.5 for uniformity of mass. In a representative 200 mg/g powder, the API is incorporated at 20.0% w/w, anhydrous citric acid and sodium citrate are used at 5.0–8.0% w/w to maintain post-reconstitution pH between 7.8 and 8.6, colloidal silicon dioxide is added at 0.5% w/w, and lactose monohydrate is added q.s. to 100.0%. The dry blend is sieved through a 500 µm conical mill and mixed in a 1500 L ribbon blender at 12 rpm for 20 min; blend uniformity is assessed by sampling 10 points, with acceptance of 90.0–110.0% of target active and relative standard deviation not more than 5.0%. The finished powder is filled into polyester/aluminium/LDPE laminate sachets at moisture below 1.5%; where stability data show moisture uptake above 2.0% at 25°C/60% RH, nitrogen sealing is applied. The terminal finished product type is a single-dose water-soluble powder sachet for oral solution administered via drinking water.

Can Direct Compression Deliver Acceptable Tablet Hardness Without Capping at 250 mg Sulfachloropyridazine Sodium?

Direct compression of sulfachloropyridazine sodium at high drug load is limited by the crystalline sodium salt's low compactability and the direct effect of residual moisture on die wall adhesion. Tablet manufacture is governed by ICH Q7 for API handling and Ph. Eur. 2.9.5 for uniformity of mass; immediate-release performance is controlled under Ph. Eur. 2.9.1 for disintegration and Ph. Eur. 2.9.3 for dissolution where the registration file requires it. For a 250 mg active tablet with total mass 400 mg, the API fraction is 62.5% w/w. The external phase consists of microcrystalline cellulose PH-102 at 26.0% w/w, crospovidone at 5.0% w/w, sodium stearyl fumarate at 1.5% w/w, and anhydrous colloidal silica at 0.5% w/w. Magnesium stearate is replaced with sodium stearyl fumarate to reduce the risk of hydrophobic over-lubrication at prolonged blending times. Where direct compression shows capping or lamination, the process is converted to roller compaction at 8–12 kN/cm and the granulate is milled through a 0.8 mm screen before compression on a 16-station rotary press at 12–18 kN and turret speed 30–40 rpm. Tablet hardness is maintained at 5–8 kP, friability at ≤1.0% after 100 drops, and particle size D90 for direct compression is controlled below 250 µm with loss on drying below 1.0%. The terminal finished product type is a scored oral tablet for veterinary prescription use.

Low-Dust Granule Premix Carriers and Segregation Control in Swine Feed Lines

Medicated feed premix granules are produced as low-dust microgranules to ensure uniform distribution across swine and poultry feed where the target registration permits use. The regulatory framework for this dosage form includes EU feed hygiene Regulation EC 183/2005, ISO 22000, and GMP+ certification requirements where the premix enters the medicated feed chain. A 10.0% w/w active granule is loaded at 100 g sulfachloropyridazine sodium per kilogram premix. Lactose monohydrate or wheat bran carrier is included at 75.0–82.0% w/w, povidone K30 binder at 2.0–3.0% w/w, and vegetable oil at 0.5–1.0% w/w to suppress dust. The premix is metered at 1 kg premix per tonne finished feed, giving an arithmetic active concentration of 100 mg per kg feed; inclusion rate is adjusted to species-specific registration data and is not a therapeutic recommendation. Granulation is performed in a fluid-bed granulator with top-spray atomization at inlet air temperature 55–60°C, product temperature 38–42°C, spray rate 120–180 g/min for a 50 kg charge, and drying to loss on drying ≤1.5%. Particle size is maintained at 150–710 µm, with fines below 100 µm not exceeding 5.0% to reduce segregation in screw and auger feed lines. The dried granule is blended in a double-cone blender for 15 min and packed into 25 kg paper-polyethylene sacks. The terminal finished product type is a low-dust medicated feed premix granule.

When Sodium Salt Selection Replaces Free Acid for Aqueous Injectable Formulations

Aqueous injectable solutions of sulfachloropyridazine sodium are produced by dissolving the sodium salt directly in Water for Injection; the sodium salt is selected over the free acid because the free acid cannot maintain sufficient aqueous solubility at the required concentration. Injectable manufacture falls under Ph. Eur. 5.1.1 sterilisation method validation, ISO 13408-1 aseptic processing, 21 CFR 211.113 control of microbiological contamination, and ICH Q3D elemental impurity risk assessment. A 200 mg/mL injectable solution contains 20.0% w/v API. The solution pH is adjusted to 8.5–9.5 with 0.1 M sodium hydroxide; sodium metabisulfite at 0.1% w/v and disodium edetate at 0.01% w/v are included only after compatibility studies demonstrate no oxidative or metal-catalyzed degradation. Sodium chloride is added to achieve 290–320 mOsm/kg. Mixing is performed in a jacketed stainless steel vessel at 15–25°C under nitrogen purge. The solution is clarified through a 0.45 µm PVDF prefilter and sterilized through a 0.22 µm PES membrane; filter integrity is confirmed by bubble point testing before aseptic filling into 10 mL or 50 mL amber type I glass vials with bromobutyl rubber stoppers. Terminal steam sterilization is generally avoided because of pH-dependent hydrolysis of the sulfonamide ring; the process therefore relies on aseptic filtration and laminar-flow filling. Admixture with acidic vehicles or calcium-containing infusion fluids requires a precipitation stress test under Ph. Eur. 2.2.1 because solubility falls under acidic conditions. The terminal finished product type is an injectable solution for veterinary parenteral administration.

Hard gelatin capsules filled with sulfachloropyridazine sodium granular blends are used for veterinary pharmacy and small-batch prescription dispensing where a fixed tablet score does not provide the required dose interval. The capsule filling operation is governed by ICH Q7 and finished capsule testing under Ph. Eur. 2.9.5 for uniformity of mass and Ph. Eur. 2.9.1 for disintegration. A size 1 capsule with total fill weight 350 mg contains the API at 60.0–70.0% w/w, corresponding to 210–245 mg sulfachloropyridazine sodium per capsule. Pregelatinized starch is used at 20.0–30.0% w/w, croscarmellose sodium at 3.0% w/w, and sodium stearyl fumarate at 1.0% w/w. The API is milled below 180 µm to reduce hopper segregation. Blending is performed in a 300 L V-blender at 15 rpm for 20 min, followed by capsule filling on a dosator machine with tamping pins; in-process weight checks are taken every 10 min with acceptance ±5.0% of target fill weight. The filling suite is maintained at 20–25°C and 40–45% RH to prevent the sodium salt from adhering to contact surfaces. The terminal finished product type is a hard gelatin capsule for oral administration.